Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

Robinson, 1999, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch Gen Psychiatry, 56, 241, 10.1001/archpsyc.56.3.241 Shepherd, 1989, The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics, Psychol Med Suppl, 15, 1, 10.1017/S026418010000059X Gilbert, 1995, Neuroleptic withdrawal in schizophrenic patients: a review of the literature, Arch Gen Psychiatry, 52, 173, 10.1001/archpsyc.1995.03950150005001 Kane, 2003, Optimising pharmacologic treatment of psychotic disorders, J Clin Psychiatry, 64, 1 Robinson, 1999, Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder, Am J Psychiatry, 156, 544, 10.1176/ajp.156.4.544 Davis, 1975, Overview: maintenance therapy in psychiatry: I Schizophrenia, Am J Psychiatry, 132, 1237, 10.1176/ajp.132.12.1237 Ray, 2009, Atypical antipsychotic drugs and the risk of sudden cardiac death, N Engl J Med, 360, 225, 10.1056/NEJMoa0806994 Tiihonen, 2009, 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), Lancet, 374, 620, 10.1016/S0140-6736(09)60742-X 2010 Tiihonen, 2011, A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia, Am J Psychiatry, 168, 603, 10.1176/appi.ajp.2011.10081224 2009 Leucht, 2003, Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials, Am J Psychiatry, 160, 1209, 10.1176/appi.ajp.160.7.1209 Chouinard, 1980, Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system, Acta Psychiatr Scand, 64, 353, 10.1111/j.1600-0447.1981.tb00794.x Komossa Higgins, 2008 Carpenter, 1990, Continuous versus targeted medication in schizophrenic outpatients: outcome results, Am J Psychiatry, 147, 1138 DerSimonian, 1986, Meta-analysis in clinical trials, Contr Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Viguera, 1997, Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment, Arch Gen Psychiatry, 54, 49, 10.1001/archpsyc.1997.01830130055011 Gardner, 2010, International consensus study of antipsychotic dosing, Am J Psychiatry, 167, 686, 10.1176/appi.ajp.2009.09060802 Peters, 2008, Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry, J Clin Epidemiol, 61, 991, 10.1016/j.jclinepi.2007.11.010 Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x Arato, 2002, A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study, Int Clin Psychopharmacol, 17, 207, 10.1097/00004850-200209000-00001 Beasley, 2003, A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse, J Clin Psychopharmacol, 23, 582, 10.1097/01.jcp.0000095348.32154.ec Cooper, 2000, Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia, Psychopharmacology, 150, 237, 10.1007/s002130000452 Gardos, 1984, Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures, Arch Gen Psychiatry, 41, 1030, 10.1001/archpsyc.1983.01790220020003 Kramer, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, J Clin Psychopharmacol, 27, 6, 10.1097/JCP.0b013e31802dda4a Leff, 1971, Trial of maintenance therapy in schizophrenia, BMJ, 3, 599, 10.1136/bmj.3.5775.599 Chen, 2010, Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial, BMJ, 341, c4024, 10.1136/bmj.c4024 Denijs, 1973, Pimozide (OrapR, R 6238) in residual schizophrenia: a clinical evaluation with long-term double-blind follow-up, Psychiatr Neurol Neurochir, 76, 47 Altman, 1998, Confidence intervals for the number needed to treat, BMJ, 317, 1309, 10.1136/bmj.317.7168.1309 Cheung, 1981, Schizophrenics fully remitted on neuroleptics for 3–5 years—to stop or continue drugs?, Br J Psychiatry, 138, 490, 10.1192/bjp.138.6.490 Sampath, 1992, Neuroleptic discontinuation in the very stable schizophrenic patient—relapse rates and serum neuroleptic levels, Hum Psychopharmacol, 7, 255, 10.1002/hup.470070405 Crow, 1986, A randomised controlled trial of prophylactic neuroleptic treatment, Br J Psychiatry, 148, 120, 10.1192/bjp.148.2.120 Boonstra, 2011, Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial, Int J Psychiatry Clin Pract, 15, 128, 10.3109/13651501.2010.534801 Caffey, 1964, Discontinuation or reduction of chemotherapy in chronic schizophrenics, J Chronic Dis, 17, 347, 10.1016/0021-9681(64)90075-X Hough, 2010, Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, Schizophr Res, 116, 107, 10.1016/j.schres.2009.10.026 Kane, 2011, A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment, J Clin Psychiatry, 72, 349, 10.4088/JCP.10m06306 Levine, 1980, Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study, Adv Biochem Psychopharmacol, 24, 483 Peuskens, 2007, Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients, Psychiatry, 4, 34 Pigott, 2003, Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study, J Clin Psychiatry, 64, 1048, 10.4088/JCP.v64n0910 Nishikawa, 1982, Prophylactic effect of neuroleptics in symptom-free schizophrenia, Psychopharmacology, 77, 301, 10.1007/BF00432759 Pietzcker, 1993, Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia—2-year results of a German multicenter study, J Psychiatr Res, 27, 321, 10.1016/0022-3956(93)90059-B Hogarty, 1974, Drug and sociotherapy in the aftercare of schizophrenic patients: II two-year relapse rates, Arch Gen Psychiatry, 31, 603, 10.1001/archpsyc.1974.01760170005001 Hogarty, 1973, Drug and sociotherapy in the aftercare of schizophrenic patients: one-year relapse rates, Arch Gen Psychiatry, 28, 54, 10.1001/archpsyc.1973.01750310038007 Greenberg, 1966, Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients, Am J Psychiatry, 123, 221, 10.1176/ajp.123.2.221 Schooler, 1982, Research diagnosis for tardive dyskinesia, Arch Gen Psychiatry, 39, 468 Gleeson, 2010, A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis, Schizophr Res, 119, 79, 10.1016/j.schres.2010.02.1073 Schulz, 2010, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ, 340, c332, 10.1136/bmj.c332 Leucht, 2009, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet, 373, 31, 10.1016/S0140-6736(08)61764-X Davis, 1994, Depot antipsychotic drugs: place in therapy, Drugs, 47, 741, 10.2165/00003495-199447050-00004 Leucht, 2011, Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials, Schizophr Res, 127, 83, 10.1016/j.schres.2010.11.020